Evidence map›Paper›PMID 41051795›Full record

ReviewChemical reviews2025

Chromatin Regulatory Targets for Anticancer Therapeutics.

Paige A Barta, Trever R Carter, Michael A Erb

Abstract readReview
In one paragraph

Review in Chemical reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paige A BartaDepartment of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.
Trever R CarterDepartment of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.
Michael A ErbDepartment of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.ORCID 0000-0001-9993-3481

Funding

Cancer-specific dependencies within the NuRD chromatin remodeler complex: new targets and chemical toolsR01CA280720 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI Michael A Erb · 2024 to 2026
$1.7M
NCI NIH HHS R01 CA280720
6 · The paper itself

Abstract

Chromatin serves to organize and compact the genome but also functions as a signaling hub for the dynamic regulation of transcriptional programs that control cell type specification. The historical discovery that several pro-differentiation anti-cancer agents target chromatin regulatory enzymes buoyed early interest in developing drugs that modulate chromatin structure and function. Chromatin-based drug discovery has since flourished alongside major advances in discovery chemistry and target selection, producing a rich collection of chemical probes, drugs, and drug candidates targeting chromatin regulatory processes. The substantial growth and maturity of this field over the last several decades provides an opportunity to reflect on the successes and failures associated with translating chromatin regulatory targets into anti-cancer drugs. Taking a target-centric perspective, we discuss the motivation for pursuing specific chromatin regulatory proteins and review the chemistries that enabled small molecule discovery and development. In so doing, we hope to evaluate the strength of these targets, the agents that prosecute them, and the prospects for future efforts in this field.

Indexed as

Antineoplastic AgentsChromatinNeoplasmsAnimalsDrug DiscoveryHumansSmall Molecule LibrariesAntineoplastic AgentsChromatinSmall Molecule Libraries

Identifiers

PMID41051795
PMCPMC12684288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.